Fujian Haixi Pharma says FDA grants fast track status to HX9428 for wet AMDPUBT·Aug 17 at 06:45 AM02637+2.37%
Fujian Haixi Pharmaceuticals schedules board meeting to review interim resultsPUBT·Aug 12 at 04:40 AM02637+2.37%
Fujian Haixi Pharmaceuticals shifts auditor as it adopts Chinese accounting standardsTip Ranks·Aug 11 at 06:41 AM02637+2.37%
Fujian Haixi Pharma clarifies auditor switch driven by CASBE reporting demands, not Deloitte disputePUBT·Aug 11 at 06:12 AM02637+2.37%
Haixi Pharmaceuticals Advances Oral nAMD Drug HX9428 With U.S. FDA Nod and New China TrialTip Ranks·Aug 4 at 04:38 AM02637+2.37%
Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trialPUBT·Aug 4 at 04:13 AM02637+2.37%REGN-2.25%
Fujian Haixi Pharma shareholders approved external auditor change at EGMPUBT·Aug 4 at 03:55 AM02637+2.37%
Fujian Haixi Pharmaceuticals files board, board committee member list with disclosure rolesPUBT·Aug 4 at 03:55 AM02637+2.37%
Fujian Haixi Pharma discloses RMB 577.22 million investments equal to 31.3% of 2025 total assetsPUBT·Aug 3 at 03:33 AM02637+2.37%
Fujian Haixi Pharma Calls 2026 EGM to Approve Auditor Change and New DirectorTip Ranks·Jul 15 at 06:08 AM02637+2.37%
Fujian Haixi Pharmaceuticals plans auditor switch to RSM China from DeloittePUBT·Jul 15 at 05:33 AM02637+2.37%
Fujian Haixi Pharma says China NMPA clears HXP089 IND for glioblastoma trialPUBT·Jul 14 at 04:08 AM02637+2.37%
Haixi Pharmaceuticals Launches Phase III Trial for Novel Osteosarcoma DrugTip Ranks·Jul 9 at 04:11 AM02637+2.37%
Guotai Haitong Keeps Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)Tip Ranks·Jul 3 at 12:15 AM02637+2.37%
